科研队伍
张金方



 最后学位:哲学博士(PhD,北京大学)

 职称职务:教授、博导

 专    业:生物化学与分子生物学

 研究方向:肿瘤靶向及免疫治疗的分子机制

 电话号码:

 E-mail: jinfang_zhang@whu.edu.cn



文化经历

2001-2005 南阳师范学会生物系,学士

2005-2008 首都师范大会员命科学学会,硕士

2008-2012 北京大会员命科学学会,博士


工作经历与任职

2012-2013 中国科学会微生物研究所,助理研究员

2013-2015 美国哈佛医学会,Beth Israel Deaconess Medical Center,博士后

2015-2018 美国哈佛医学会/哈佛牙医学会,讲师(Instructor)

2018-至今 澳门百老汇4001登录网站,教授


获奖情况

2012 北京大学优秀毕业生

2012 北京市优秀毕业生

2017 美国国立卫生研究会/国家癌症研究中心(NIH/NCI)K99/R00基金资助

2018 哈佛医学会华人学者生命科学杰出研究成果奖


研究领域

   相对于传统的放疗和化疗,新兴的肿瘤靶向和免疫治疗是当今肿瘤治疗领域研究的热点和前沿问题。然而,这两种疗法也都有自身的局限性,例如:肿瘤耐药性以及免疫逃逸问题。针对这些问题,本课题组将整合生物化学、分子生物学、细胞生物学和体内疾病模型等多种技术手段,从分子、细胞、以及动物个体水平等多个层次阐述肿瘤耐药以及免疫逃逸的分子机制。这些研究成果将为临床上肿瘤的治疗提供新的、有效的治疗方案和策略。


代表性论文

1. Zhang J*, Bu X*, Wang H*, Zhu Y, Geng Y, Nihira NT, Tan Y, Ci Y, Wu F, Dai X, Guo J, Huang YH, Fan C, Ren S, Sun Y, Freeman GJ#, Sicinski P#, Wei W# (2018). Cyclin D-CDK4 kinase destabilizes PD-L1 via Cul3SPOP to control cancer immune surveillance. Nature, 553(7686): 91-95.

2. Zhang J*, Dang F*, Ren J, Wei W (2018). PD-L1 regulation and its role in cancer immunotherapy. Trends in Biochemical Sciences, 43(12): 1014-1032.

3. Zhang J*, Chen M*, Zhu Y*, Dai X, Ren J, Ren S, Shulga YV, Beca F, Gan W, Wu F, Lin YM, DeCaprio JA, Beck AH, Lu KP, Huang J, Zhao C, Sun Y, Gao X#, Pandolfi PP#, Wei W# (2018). SPOP promotes Nanog destruction to suppress stem cell traits and prostate cancer progression. Developmental Cell, published online Dec. 27, 2018.

4. Wan L*, Xu K*, Wei Y*, Zhang J*, Han T, Fry C, Zhang Z, Wan Y, Huang L, Yuan M, Xia W, Chang W, Huang W, Liu C, Chang Y, Liu J, Wu Y, Jin V, Dai X, Guo J, Liu J, Jiang S, Li J, Asara JM, Brown M, Hung MC, Wei W (2018). Phosphorylation of EZH2 by AMPK suppresses PRC2 methyltransferase activity and oncogenic function. Molecular Cell, 69(2): 279-291.

5. Wu F, Dai X, Gan W, Wan L, Li M, Mitsiades N, Wei W, Ding Q#, Zhang J# (2017). Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation. Cancer Letters, 385: 207-214.

6. Wang B*, Jie Z*, Joo D, Ordureau A, Liu P, Gan W, Guo J, Zhang J, North BJ, Dai X, Cheng X, Bian X, Zhang L, Harper JW, Sun S# and Wei W# (2017). TRAF2 and OTUD7B govern a ubiquitin-dependent switch regulating mTORC2 signaling complex. Nature, 545(7654): 365-369.

7. Zhang J*, Xu K*, Liu P, Geng Y, Wang B, Gan W, Guo J, Wu F, Chin YR, Berrios C, Lien EC, Toker A, DeCaprio JA, Sicinski P, Wei W (2016). Inhibition of Rb phosphorylation leads to mTORC2-mediated activation of Akt. Molecular Cell, 62(6): 929-942.

8. Guo J, Chakraborty AK, Liu P, Gan W, Zheng X, Inuzuka H, Wang B, Zhang J, Zhang, L, Novak, J, Yuan, M, Cheng, JQ, Toker, A, Signroretti, S, Zhang, Q, Asara, JM, Kaelin, Jr, WG, Wei, W (2016). pVHL suppresses kinase activity of Akt in a proline-hydroxylation dependent manner. Science, 353(6302): 929-932.

9. Wang L*, Zhang J*, Wan L*, Zhou X, Wang Z, Wei W (2015). Targeting Cdc20 as a novel cancer therapeutic strategy. Pharmacology & Therapeutics, 151: 141-151.

10. Zhang J*, Wan L*, Dai X, Sun Y, Wei W (2014). Functional characterization of Anaphase Promoting Complex/Cyclosome (APC/C) E3 ubiquitin ligases in tumorigenesis. Biochim Biophys Acta (BBA)-Reviews on Cancer, 1845(2): 277-293.

11. Zhang J, Bai D, Ma X, Guan J, Zheng X (2014). hCINAP is a novel regulator of ribosomal protein-HDM2-p53 pathway by controlling NEDDylation of ribosomal protein S14. Oncogene, 33(2): 246-254.

12. Zhang J, Zhang F, Zheng X (2010). Depletion of hCINAP by RNA interference causes defects in Cajal body formation, histone transcription, and cell viability. Cell Mol Life Sci, 67:1907-1918.

课题组积极招收会员和博士后加入!

上一条:宋威 下一条:俞雁寻

地 址:湖北省武汉市武昌区东湖路115号 邮政编码:430071 电 话:027-68750205  邮 箱:mri@whu.edu.cn

CopyRight© 2016  版权所踊岷澳门百老汇4001登录网站

XML 地图 | Sitemap 地图